Salute e Benessere
Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
At Daiichi Sankyo, Dr. Yver served as Global Head of Oncology R&D, and at AstraZeneca, he led the oncology development programs. His leadership in bringing ENHERTU, a pioneering ADC for breast cancer, from initial first-in-human clinical studies to global approval, exemplifies his deep expertise and will be invaluable to Ona as it advances its innovative ADC pipeline toward clinical development.
,
Dr. Yver is currently an Independent Director on the Board of Sanofi, where he contributes strategic and scientific insight at the governance level. He also serves on the boards of several oncology-focused companies, as well as the scientific advisory committee for Gustave Roussy Cancer Institute, further demonstrating his broad scientific and business influence and commitment to advancing cancer therapies.
Ona's proprietary patient-based discovery platform uniquely unlocks new biological targets that are not exploited by current ADCs or standard therapies, giving the Company a significant competitive edge. Its lead candidate, ONA-255, targets a unique first-in-class mechanism and is perfectly suited for the treatment of advanced cancers, particularly breast cancer. This candidate is advancing toward clinical trials in early 2026 and is also demonstrating broad potential across breast, gastric, and other solid tumors. Its second candidate, , is focused on high-unmet-need indications such as MSS colorectal cancer and hepatocellular carcinoma. Together, these programs underscore Ona's innovative approach to developing transformative therapies for difficult-to-treat solid tumors.
:
Ona Therapeutics is pioneering the development of first-in-class antibody-drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. Ona collaborates with renowned academics, clinicians, and clinical research partners. This collaborative approach enables the identification of novel therapeutic targets derived from the unique biology of treatment-refractory advanced cancer patients. Ona's approach combines biological insight with expertise in biologics to design ADCs and antibody therapies using target validation, optimized payload design, and validated linker-payload technology to provide effective treatments for patients with limited options. Its precision-engineered ADC pipeline consists of first-in-class ADCs, targeting aggressive and refractory cancer indications. The lead ADC, ONA-255, targeting breast cancer and solid tumors is in active IND development and will enter clinical development in early 2026. The company is also expanding its target indications into additional aggressive cancer types, including gastric, liver, and colon cancers. For further information visit our new website here https://ona-therapeutics.com/
View original content:https://www.prnewswire.co.uk/news-releases/ona-therapeutics-appoints-oncology-drug-development-veteran-dr-antoine-yver-as-chair-to-accelerate-adc-programs-to-clinical-inflection-points-302582175.html